Premium
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats
Author(s) -
Muriel MariePaule,
Orieux Gaël,
Hirsch Etienne C.
Publication year - 2002
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.10256
Subject(s) - dopamine , ropinirole , levodopa , dopamine receptor , internalization , dopamine receptor d1 , endogenous agonist , medicine , endocrinology , receptor , dopamine receptor d3 , agonist , dopamine agonist , dopamine receptor d2 , chemistry , pharmacology , parkinson's disease , dopaminergic , biology , disease
Levodopa therapy in Parkinson's disease is mediated by dopamine receptors and, in a recent study, we showed that a Dl full agonist can induce an internalization of D1 dopamine receptors. The aim of the present study was to determine whether levodopa or a dopamine agonist such as ropinirole can also induce the internalization of D1 dopamine receptors in the striatum of control and hemiparkinsonian rats. The distribution of D1 dopamine receptors was analyzed by immunohistochemistry using a specific antibody. In control animals and 6‐hydroxydopamine (6‐OHDA)‐lesioned animals treated with saline, D1 dopamine receptors were localized at the level of the plasma membrane. In contrast, in both lesioned and nonlesioned animals receiving a single dose of levodopa, but not in animals receiving ropinirole, D1 dopamine receptors were internalized in the cytoplasm. This result is likely explained by the fact that ropinirole binds to non‐D1 dopamine receptors, whereas levodopa, which increases dopamine levels, indirectly acts on both D1 and D2 receptors. Ropinirole is consequently less likely to desensitize D1 dopamine receptors than levodopa and, thus, to reduce the efficacy of the treatment. © 2002 Movement Disorder Society